COVID-19 VACCINE TRIAL VOLUNTEER HAD NEUROLOGICAL SYMPTOMS- ASTRAZENECA
AstraZeneca said a woman in the United Kingdom had symptoms consistent with a severe but rare spinal inflammatory disorder, which led to the British drugmaker’s decision to stop its clinical study of the new coronavirus vaccine.
According to Stat News, the participant was recovering and will likely be discharged from the hospital as early as today.
The new disclosures by Astra Chief Executive Pascal Soriot were shared by three of the investors participating in conference calls.
The London-listed firm said late Tuesday it would pause global trials of its COVID-19 vaccine candidate after an unexplained illness in a study participant.